Shank‑associated RH domain interactor signaling in tumorigenesis (Review)
- Authors:
- Chong Zeng
- Dan Xiong
- Ketao Zhang
- Jie Yao
-
Affiliations: Medical Research Center, Shunde Hospital, Southern Medical University, The First People's Hospital of Shunde, Foshan, Guangdong 528308, P.R. China, Department of Hematology, Shunde Hospital, Southern Medical University, The First People's Hospital of Shunde, Foshan, Guangdong 528308, P.R. China, Department of Hepatobiliary Surgery, Shunde Hospital, Southern Medical University, The First People's Hospital of Shunde, Foshan, Guangdong 528308, P.R. China - Published online on: July 9, 2020 https://doi.org/10.3892/ol.2020.11850
- Pages: 2579-2586
-
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the Human development index (2008–2030): A population-based study. Lancet Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Luo J, Solimini NL and Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell. 136:823–837. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tamiya H, Kim H, Klymenko O, Kim H, Feng Y, Zhang T, Han JY, Murao A, Snipas SJ, Jilaveanu L, et al: SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth. J Clin Invest. 128:517–530. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jung J, Kim JM, Park B, Cheon Y, Lee B, Choo SH, Koh SS and Lee S: Newly identified tumor-associated role of human Sharpin. Mol Cell Biochem. 340:161–167. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ojo D, Wu Y, Bane A and Tang D: A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer. Biochim Biophys Acta Mol Basis Dis. 1864:735–745. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bii VM, Rae DT and Trobridge GD: A novel gammaretroviral shuttle vector insertional mutagenesis screen identifies SHARPIN as a breast cancer metastasis gene and prognostic biomarker. Oncotarget. 6:39507–39520. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Seymour RE, Hasham MG, Cox GA, Shultz LD, Hogenesch H, Roopenian DC and Sundberg JP: Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun. 8:416–421. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Potter CS, Sundberg JP and Hogenesch H: SHARPIN is a key regulator of immune and inflammatory responses. J Cell Mol Med. 16:2271–2279. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rittinger K and Ikeda F: Linear ubiquitin chains: Enzymes, mechanisms and biology. Open Biol. 7:1700262017. View Article : Google Scholar : PubMed/NCBI | |
|
Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, Tanaka K, Nakano H and Iwai K: SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature. 471:633–636. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Peltzer N, Darding M, Montinaro A, Draber P, Draberova H, Kupka S, Rieser E, Fisher A, Hutchinson C, Taraborrelli L, et al: LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. Nature. 557:112–117. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Y, Joo D, Liu G, Tu H, You J, Jin J, Zhao X, Hung MC and Lin X: Linear ubiquitination of cFLIP induced by LUBAC contributes to TNFα-induced apoptosis. J Biol Chem. 293:20062–20072. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, van Wijk SJ, Goswami P, Nagy V, Terzic J, et al: SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature. 471:637–641. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Teh CE, Lalaoui N, Jain R, Policheni AN, Heinlein M, Alvarez-Diaz S, Sheridan JM, Rieser E, Deuser S, Darding M, et al: Linear ubiquitin chain assembly complex coordinates late thymic T-cell differentiation and regulatory T-cell homeostasis. Nat Commun. 7:133532016. View Article : Google Scholar : PubMed/NCBI | |
|
Redecke V, Chaturvedi V, Kuriakose J and Hacker H: SHARPIN controls the development of regulatory T cells. Immunology. 148:216–226. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Z, Tang J, Yang Q, Li X, Zhu J and Wu G: Atypical ubiquitin-binding protein SHARPIN promotes breast cancer progression. Biomed Pharmacother. 119:1094142019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Yu S, Wang W, Li X, Hou Y, Liu Z, Shi Y, Mu K, Niu G, Xu J, et al: SHARPIN facilitates p53 degradation in breast cancer cells. Neoplasia. 19:84–92. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou S, Liang Y, Zhang X, Liao L, Yang Y, Ouyang W and Xu H: SHARPIN promotes melanoma progression via Rap1 signaling pathway. J Invest Dermatol. 140:395–403.e6. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
De Melo J, Wu V, He L, Yan J and Tang D: SIPL1 enhances the proliferation, attachment, and migration of CHO cells by inhibiting PTEN function. Int J Mol Med. 34:835–841. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki K and Iwai K: Roles of linear ubiquitinylation, a crucial regulator of NF-κB and cell death, in the immune system. Immunol Rev. 266:175–189. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda F: Linear ubiquitination signals in adaptive immune responses. Immunol Rev. 266:222–236. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Iwai K, Fujita H and Sasaki Y: Linear ubiquitin chains: NF-κB signalling, cell death and beyond. Nat Rev Mol Cell Biol. 15:503–508. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S, et al: Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol. 11:123–132. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rivkin E, Almeida SM, Ceccarelli DF, Juang YC, MacLean TA, Srikumar T, Huang H, Dunham WH, Fukumura R, Xie G, et al: The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature. 498:318–324. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fujita H, Tokunaga A, Shimizu S, Whiting AL, Aguilar-Alonso F, Takagi K, Walinda E, Sasaki Y, Shimokawa T, Mizushima T, et al: Cooperative domain formation by homologous motifs in HOIL-1L and SHARPIN plays A crucial role in LUBAC stabilization. Cell Rep. 23:1192–1204. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Matsunaga Y, Nakatsu Y, Fukushima T, Okubo H, Iwashita M, Sakoda H, Fujishiro M, Yamamotoya T, Kushiyama A, Takahashi S, et al: LUBAC formation is impaired in the livers of mice with MCD-dependent nonalcoholic steatohepatitis. Mediators Inflamm. 2015:1253802015. View Article : Google Scholar : PubMed/NCBI | |
|
Rodgers MA, Bowman JW, Fujita H, Orazio N, Shi M, Liang Q, Amatya R, Kelly TJ, Iwai K, Ting J, et al: The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. J Exp Med. 211:1333–1347. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tokunaga F: Linear ubiquitination-mediated NF-κB regulation and its related disorders. J Biochem. 154:313–323. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Oeckinghaus A, Hayden MS and Ghosh S: Crosstalk in NF-κB signaling pathways. Nat Immunol. 12:695–708. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
D'Ignazio L, Batie M and Rocha S: Hypoxia and inflammation in cancer, focus on HIF and NF-κB. Biomedicines. 5:212017. View Article : Google Scholar | |
|
Israel A: The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol. 2:a0001582010. View Article : Google Scholar : PubMed/NCBI | |
|
Smit JJ, van Dijk WJ, El Atmioui D, Merkx R, Ovaa H and Sixma TK: Target specificity of the E3 ligase LUBAC for ubiquitin and NEMO relies on different minimal requirements. J Biol Chem. 288:31728–31737. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tokunaga F and Iwai K: Involvement of LUBAC-mediated linear polyubiquitination of NEMO in NF-kappaB activation. Tanpakushitsu Kakusan Koso. 54:635–642. 2009.(In Japanese). PubMed/NCBI | |
|
Iwai K and Tokunaga F: Linear polyubiquitination: A new regulator of NF-kappaB activation. EMBO Rep. 10:706–713. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rahighi S, Ikeda F, Kawasaki M, Akutsu M, Suzuki N, Kato R, Kensche T, Uejima T, Bloor S, Komander D, et al: Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell. 136:1098–1109. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bal E, Laplantine E, Hamel Y, Dubosclard V, Boisson B, Pescatore A, Picard C, Hadj-Rabia S, Royer G, Steffann J, et al: Lack of interaction between NEMO and SHARPIN impairs linear ubiquitination and NF-κB activation and leads to incontinentia pigmenti. J Allergy Clin Immunol. 140:1671–1682.e2. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Niu J, Shi Y, Iwai K and Wu ZH: LUBAC regulates NF-κB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J. 30:3741–3753. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lane D and Levine A: p53 Research: The past thirty years and the next thirty years. Cold Spring Harb Perspect Biol. 2:a0008932010. View Article : Google Scholar : PubMed/NCBI | |
|
Ozaki T and Nakagawara A: Role of p53 in cell death and human cancers. Cancers (Basel). 3:994–1013. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bieging KT, Mello SS and Attardi LD: Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 14:359–370. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Muller PA, Vousden KH and Norman JC: p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 192:209–218. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Scoumanne A, Zhang J and Chen X: PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res. 37:4965–4976. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Honda R, Tanaka H and Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27. 2007. View Article : Google Scholar | |
|
Lee JT and Gu W: The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 17:86–92. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lessel D, Wu D, Trujillo C, Ramezani T, Lessel I, Alwasiyah MK, Saha B, Hisama FM, Rading K, Goebel I, et al: Dysfunction of the MDM2/p53 axis is linked to premature aging. J Clin Invest. 127:3598–3608. 2007. View Article : Google Scholar | |
|
Chen J, Lin J and Levine AJ: Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med. 1:142–152. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Bayle JH, Olson D and Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126–1132. 1999. View Article : Google Scholar | |
|
Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R and Pan J: Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest. 126:3961–3980. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rehman I, Basu SM, Das SK, Bhattacharjee S, Ghosh A, Pommier Y and Das BB: PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes. Nucleic Acids Res. 46:5601–5617. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Durant ST, Cho EC and La Thangue NB: p53 methylation-the Arg-ument is clear. Cell Cycle. 8:801–802. 2008. View Article : Google Scholar | |
|
Gkountela S, Li Z, Chin CJ, Lee SA and Clark AT: PRMT5 is required for human embryonic stem cell proliferation but not pluripotency. Stem Cell Rev. 10:230–239. 2014. View Article : Google Scholar | |
|
Stopa N, Krebs JE and Shechter D: The PRMT5 arginine methyltransferase: Many roles in development, cancer and beyond. Cell Mol Life Sci. 72:2041–2059. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M, Yao B, Gui T, Guo C, Wu X, Li J, Ma L, Deng Y, Xu P, Wang Y, et al: PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression. Theranostics. 10:4437–4452. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Vinet M, Suresh S, Maire V, Monchecourt C, Nemati F, Lesage L, Pierre F, Ye M, Lescure A, Brisson A, et al: Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers. Cancer Med. 8:2414–2428. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu JM, Chen CT, Chou CK, Kuo HP, Li LY, Lin CY, Lee HJ, Wang YN, Liu M, Liao HW, et al: Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol. 13:174–181. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R, et al: Arginine methylation controls growth regulation by E2F-1. EMBO J. 31:1785–1797. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fu T, Lv X, Kong Q and Yuan C: A novel SHARPIN-PRMT5-H3R2me1 axis is essential for lung cancer cell invasion. Oncotarget. 8:54809–54820. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B and La Thangue NB: Arginine methylation regulates the p53 response. Nat Cell Biol. 10:1431–1439. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yang M, Sun J, Sun X, Shen Q, Gao Z and Yang C: Caenorhabditis elegans protein arginine methyltransferase PRMT-5 negatively regulates DNA damage-induced apoptosis. PLoS Genet. 5:e10005142009. View Article : Google Scholar : PubMed/NCBI | |
|
Bezzi M, Teo SX, Muller J, Mok WC, Sahu SK, Vardy LA, Bonday ZQ and Guccione E: Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev. 27:1903–1916. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gerhart SV, Kellner WA, Thompson C, Pappalardi MB, Zhang XP, Montes de Oca R, Penebre E, Duncan K, Boriack-Sjodin A, Le B, et al: Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci Rep. 8:97112018. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y and Diehl JA: PRMT5-dependent p53 escape in tumorigenesis. Oncoscience. 2:700–702. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Scaglione A, Patzig J, Liang J, Frawley R, Bok J, Mela A, Yattah C, Zhang J, Teo SX, Zhou T, et al: PRMT5-mediated regulation of developmental myelination. Nat Commun. 9:28402018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Cheng G, Hamard PJ, Greenblatt S, Wang L, Man N, Perna F, Xu H, Tadi M, Luciani L, et al: Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. J Clin Invest. 125:3532–3544. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Wang H, Huang Q, Liu Q, Guo Y, Lu J, Li X, Xue C and Han Q: Transcriptional repression of p53 by PAX3 contributes to gliomagenesis and differentiation of glioma stem cells. Front Mol Neurosci. 11:1872018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Zhao L, Su Q, Fan X, Wang Y, Gao S, Wang H, Chen H, Chan CB and Liu Z: Phosphorylation of MITF by AKT affects its downstream targets and causes TP53-dependent cell senescence. Int J Biochem Cell Biol. 80:132–142. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lilja J, Zacharchenko T, Georgiadou M, Jacquemet G, De Franceschi N, Peuhu E, Hamidi H, Pouwels J, Martens V, Nia FH, et al: SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras. Nat Cell Biol. 19:292–305. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JT, Shan J, Zhong J, Li M, Zhou B, Zhou A, Parsons R and Gu W: RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation. Cell Res. 23:552–564. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, et al: Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature. 453:662–666. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Worby CA and Dixon JE: Pten. Annu Rev Biochem. 83:641–669. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Wu C, Han B, Xu F, Mao M, Guo X and Wang J: Dexmedetomidine attenuates repeated propofol exposure-induced hippocampal apoptosis, PI3K/Akt/Gsk-3β signaling disruption, and juvenile cognitive deficits in neonatal rats. Mol Med Rep. 14:769–775. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nakanishi A, Wada Y, Kitagishi Y and Matsuda S: Link between PI3K/AKT/PTEN pathway and NOX proteinin diseases. Aging Dis. 5:203–211. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA and Barata JT: PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 118:3762–3774. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gomes AM, Soares MV, Ribeiro P, Caldas J, Povoa V, Martins LR, Melao A, Serra-Caetano A, de Sousa AB, Lacerda JF, et al: Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels. Haematologica. 99:1062–1068. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ and Pandolfi PP: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 465:1033–1038. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Khouri AM, Ma Y, Togo SH, Williams S and Mustelin T: Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem. 280:35195–35202. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ikenoue T, Inoki K, Zhao B and Guan KL: PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 68:6908–6912. 2018. View Article : Google Scholar | |
|
Yang JM, Schiapparelli P, Nguyen HN, Igarashi A, Zhang Q, Abbadi S, Amzel LM, Sesaki H, Quinones-Hinojosa A and Iijima M: Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. Oncogene. 36:3673–3685. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Song Z, Han X, Shen L, Zou H, Zhang B, Liu J and Gong A: PTEN silencing enhances neuronal proliferation and differentiation by activating PI3K/Akt/GSK3β pathway in vitro. Exp Cell Res. 363:179–187. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hopkins BD, Hodakoski C, Barrows D, Mense SM and Parsons RE: PTEN function: The long and the short of it. Trends Biochem Sci. 39:183–190. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Senechal K, Neshat MS, Whang YE and Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 95:15587–15591. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
He L, Ingram A, Rybak AP and Tang D: Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest. 120:2094–2108. 2012. View Article : Google Scholar | |
|
De Melo J, Lin X, He L, Wei F, Major P and Tang D: SIPL1-facilitated PTEN ubiquitination contributes to its association with PTEN. Cell Signal. 26:2749–2756. 2014. View Article : Google Scholar : PubMed/NCBI |
